Targeting of cancer stem cells by inhibitors of DNA and histone methylation

Bibliography

• Christophersen NS, Helin K. Epigenetic control of embryonic stem cell fate. J Exp Med 2010;207:2287–95
   PubMed Web of Science ®Google Scholar
• Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013;153:38–55
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group genes: keeping stem cell activity in balance. PLoS Biol 2008;6:e113
   PubMedGoogle Scholar
• Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006;125:301–13
   PubMed Web of Science ®Google Scholar
• Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006;441:349–53
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov 2014;13:497–512
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–7
   PubMed Web of Science ®Google Scholar
• Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012;22:837–49
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11:726–34
   PubMed Web of Science ®Google Scholar
• Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet 2013;14:204–20
   PubMed Web of Science ®Google Scholar
• Momparler RL. Pharmacology of 5-Aza-2’-deoxycytidine (Decitabine). Semin Hematol 2005;42:S9–S16
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Steele R, Ray RB. MBP-1 physically associates with histone deacetylase for transcriptional repression. Biochem Biophys Res Commun 1999;260:405–9
   PubMed Web of Science ®Google Scholar
• Deneberg S, Grövdal M, Karimi M, et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia 2010;24:932–41
   PubMed Web of Science ®Google Scholar
• Tessema M, Yu YY, Stidley CA, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009;30:1132–8
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13:484–92
   PubMed Web of Science ®Google Scholar
• Malik P, Cashen AF. Decitabine in the treatment of acute leukemia in elderly patients. Cancer Manag Res 2014;6:53–61
   PubMed Web of Science ®Google Scholar
• Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-Aza-2-deoxycytidine in patients with acute leukemia. Pharm Ther 1986;30:277–86
   Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635–40
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271–9
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884–91
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473–8
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556–61
   PubMed Web of Science ®Google Scholar
• Momparler RL, Bouffard DY, Momparler LF, et al. Pilot phase I-II study on 5-aza-2’-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8:358–68
   PubMed Web of Science ®Google Scholar
• Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598–607
   PubMed Web of Science ®Google Scholar
• Raynal NJ, Si J, Taby RF, et al. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 2012;72:1170–81
   Google Scholar
• Pandiyan K, You JS, Yang X, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013;41:3973–85
   PubMed Web of Science ®Google Scholar
• Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741–50
   PubMed Web of Science ®Google Scholar
• Si J, Boumber YA, Shu J, et al. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 2010;70:6968–77
   Google Scholar
• Momparler RL, Côté S, Momparler LF, et al. Epigenetic therapy of acute myeloid leukemia using 5-aza-2’-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clinical Epigenetics 2014;6:19
   PubMed Web of Science ®Google Scholar
• Lemaire M, Momparler LF, Farinha NJ, et al. Enhancement of antineoplastic action of 5-aza-2’-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Leuk Lymphoma 2004;45:147–54
   PubMed Web of Science ®Google Scholar
• Momparler RL, Idaghdour Y, Marquez VE, et al. Synergistic antileukemic action of inhibitors of DNA methylation and histone methylation. Leuk Res 2012;36:1049–54
   PubMed Web of Science ®Google Scholar
• Rajasekhar VK, Begemann M. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 2007;25:2498–510
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010;7:299–313
   PubMed Web of Science ®Google Scholar
• Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846–56
   PubMed Web of Science ®Google Scholar
• Suvà ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009;69:9211–18
   PubMed Web of Science ®Google Scholar
• Herrera-Merchan A, Arranz L, Ligos JM, et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012;3:623
   PubMed Web of Science ®Google Scholar
• Tanaka S, Miyagi S, Sashida G, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012;120:1107–17
   PubMed Web of Science ®Google Scholar
• Marchesi I, Bagella L. Role of enhancer of zeste homolog 2 polycomb protein and its significance in tumor progression and cell differentiation. Biochemistry, Genetics and Molecular Biology, “Chromatin Remodelling”, Chapter 6, book edited by Danuta Radzioch, ISBN 978-953-51-1087-3, Published: April 17, 2013
   Google Scholar
• Sato T, Kaneda A, Tsuji S, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 2013;3:1911
   PubMed Web of Science ®Google Scholar
• Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia 2014;28:44–9
   PubMed Web of Science ®Google Scholar
• Wu Z, Lee ST, Qiao Y, et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 2011;18:1771–9
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108–12
   PubMed Web of Science ®Google Scholar
• Ezponda T, Licht JD. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin Cancer Res 2014;20:5001–8
   PubMed Web of Science ®Google Scholar
• Kim JH, Sharma A, Dhar SS, et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 2014;74:1705–17
   PubMed Web of Science ®Google Scholar
• Glazer RI, Hartman KD, Knode MC, et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 1986;135:688–94
   PubMed Web of Science ®Google Scholar
• Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer 2009;8:1579–88
   Web of Science ®Google Scholar
• Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114:2733–43
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Gene Dev 2007;21:1050–63
   PubMed Web of Science ®Google Scholar
• Sun F, Chan E, Wu Z, et al. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther 2009;8:3191–202
   PubMed Web of Science ®Google Scholar
• Zhang L, Deng L, Chen F, et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 2014;5(21):10665–77
   PubMed Web of Science ®Google Scholar
• McLean CM, Karemaker ID, van Leeuwen F. The emerging roles of DOT1L in leukemia and normal development. Leukemia 2014;28:2131–8
   PubMed Web of Science ®Google Scholar
• Tian X, Zhang S, Liu HM, et al. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets 2013;13:558–79
   PubMed Web of Science ®Google Scholar
• Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014;13:842–54
   PubMed Web of Science ®Google Scholar
• Ribrag V, Soria1 J-C, Reyderman L, et al. Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438. Ann Oncol 2015;26(Suppl 2):ii10
   Google Scholar
• Balasubramanian V, Iyer P, Arora S, et al. CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 Apr 2014; San Diego, CA. Cancer Res 2014. 74(19 Suppl):abstract 1697
   Google Scholar
• Verma SK, Tian X, LaFrance LV, et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 2012;3:1091–6
   PubMed Web of Science ®Google Scholar
• Amatangelo MD, Garipov A, Li H, et al. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 2013;12:2113–19
   PubMed Web of Science ®Google Scholar
• Qi W, Chan H, Teng L, et al. Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012;109:21360–5
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157–8
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871–4
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232–6
   PubMed Web of Science ®Google Scholar
• Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics 2013;5:3
   PubMed Web of Science ®Google Scholar
• Melnick A. Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer Cell 2012;22:569–70
   PubMed Web of Science ®Google Scholar
• Lemaire M, Chabot GG, Raynal NJ, et al. Importance of dose-schedule of 5-aza-2’-deoxycytidine for the epigenetic therapy of cancer. BMC Cancer 2008;8:128
   PubMedGoogle Scholar
• Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013;339:1567–70
   PubMed Web of Science ®Google Scholar
• Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695–9
   PubMed Web of Science ®Google Scholar
• Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012;488:43–8
   PubMed Web of Science ®Google Scholar
• Young JD, Yao SY, Baldwin JM, et al. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med 2013;34:529–47
   PubMed Web of Science ®Google Scholar
• Hung SW, Mody H, Marrache S, et al. Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies. PLoS One 2013;8:e71196
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583–92
   PubMed Web of Science ®Google Scholar
• Zhou J, Bi C, Cheong LL, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011;18:2830–9
   Google Scholar
• Ueda K, Yoshimi A, Yuki Kagoya Y, et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci 2014;105:512–19
   PubMed Web of Science ®Google Scholar
• Benoit YD, Witherspoon MS, Laursen KB, et al. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cancer Res 2013;319:1463–70
   Google Scholar
• Li Z, Wang Y, Qiu J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget 2013;4:2532–49
   PubMedGoogle Scholar
• Smits M, Mir SE, Nilsson RJ, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 2011;6:e16282
   PubMed Web of Science ®Google Scholar
• Au SL, Wong CC, Lee JM, et al. EZH2-mediated H3K27me3 is involved in epigenetic repression of deleted in liver cancer 1 in human cancers. PLoS ONE 2013;8:e68226
   PubMed Web of Science ®Google Scholar
• Pandiyan K, You JS, Yang X, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013;41:3973–85
   PubMed Web of Science ®Google Scholar
• Lübbert M, Rüter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012;97:393–401
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Saitoh H, Inoue A, et al. 3-Deazaneplanocin A (DZNep), an inhibitor of S -adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation. J Biol Chem 2014;289:8121–34
   PubMed Web of Science ®Google Scholar
• Fiskus W, Rao R, Balusu R, et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res 2012;18:6227–38
   PubMed Web of Science ®Google Scholar
• Hayden A, Johnson PW, Packham G, et al. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat 2011;127:109–19
   PubMed Web of Science ®Google Scholar
• Puppe J, Drost R, Liu X, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 2009;11:R63
   PubMed Web of Science ®Google Scholar
• Cheng LL, Itahana Y, Lei ZD, et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res 2012;18:4201–12
   PubMed Web of Science ®Google Scholar
• Lee JK, Kim KC. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem Biophys Res Commun 2013;438:647–52
   PubMed Web of Science ®Google Scholar
• Kikuchi J, Takashina T, Kinoshita I, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012;78:138–43
   PubMed Web of Science ®Google Scholar
• Kemp CD, Rao M, Xi S, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 2012;18:77–90
   PubMed Web of Science ®Google Scholar
• Kalushkova A, Fryknäs M, Lemaire M, et al. Polycomb target genes are silenced in multiple myeloma. PLoS ONE 2010;5:e11483
   PubMed Web of Science ®Google Scholar
• Xie Z, Bi C, Cheong LL, et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One 2011;6:e21583
   PubMed Web of Science ®Google Scholar
• Wu Z, Lee ST, Qiao Y, et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 2011;18:1771–9
   PubMed Web of Science ®Google Scholar
• Avan A, Crea F, Paolicchi E, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-Deazaneplanocin A with Gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012;11:1735–46
   PubMed Web of Science ®Google Scholar
• Wee ZN, Li Z, Lee PL, et al. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep 2014;8:204–16
   PubMed Web of Science ®Google Scholar
• Chiba T, Suzuki E, Negishi M, et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012;130:2557–67
   PubMed Web of Science ®Google Scholar
• Smits M, Nilsson J, Mir SE, et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010;1:710–20
   PubMedGoogle Scholar